New Daily Supplement Provides Effective Relief and Better Breast Health.
A recent Harris Poll survey supports what millions of many women already know – a typical menstrual cycle can mean more than just stomach cramps and fatigue. The survey – conducted across a sample of women ages 24-45 – shows that 68% of women also suffer from monthly breast discomfort related to their cycle. Even worse, 45% of respondents don’t think there is an effective treatment to alleviate the heaviness, aches and discomfort that is thought to be caused by the influx of hormones during that time of the month.
Luckily, according to Dr. Lisa Masterson, OB/GYN and co-host of TV’s “The Doctors,” there is a solution. “Molecular iodine supplements can help women reduce the symptoms of menstrual-related breast tenderness, swelling, aches and heaviness,” says Masterson. “In most cases, these symptoms will improve noticeably within 60 days of starting a daily molecular iodine regimen…research has shown that up to 74% of women experienced improvement in their breast discomfort.”
There is a new molecular iodine supplement – called Violet iodine – that addresses this breast discomfort issue and is available without a prescription. As it turns out, the active ingredient in Violet iodine can also help women take care of their long-term breast health every single day.
As Dr. Masterson explains, there are other benefits to taking a daily molecular iodine supplement. “It’s unfortunate that many women, who likely already take vitamins and supplements for a variety of health benefits, do not know that molecular iodine may significantly improve the health of their breasts by reducing fibrocystic breast tissue,” says Dr. Masterson. “Taking one pill a day can help to end the discomfort and improve breast health.”
The bottom line? Violet iodine provides two pretty amazing benefits in one simple daily supplement. To learn more about Violet iodine, and where to buy it, visit VioletDaily.com
About the Survey
The survey was conducted online within the United States between July 31 and August 5, 2015, among 985 U.S. women ages 25 and older, among whom 400 are age 25-45, by Harris Poll on behalf of BioPharmX Corporation via its Quick Query omnibus product. Figures for age, sex, race/ethnicity, education, region and household income were weighted where necessary to bring them into line with their actual proportions in the population. Propensity score weighting was used to adjust for respondents’ propensity to be online.
All sample surveys and polls, whether or not they use probability sampling, are subject to multiple sources of error which are most often not possible to quantify or estimate, including sampling error, coverage error, error associated with nonresponse, error associated with question wording and response options, and post-survey weighting and adjustments. Therefore, the words “margin of error” are avoided as they are misleading. All that can be calculated are different possible sampling errors with different probabilities for pure, unweighted, random samples with 100 percent response rates. These are only theoretical because no published polls come close to this ideal.
Respondents for this survey were selected from among those who have agreed to participate in our surveys. The data have been weighted to reflect the composition of the adult population. Because the sample is based on those who agreed to participate in the online panel, no estimates of theoretical sampling error can be calculated.